Adial Pharmaceuticals CEO Cary Claiborne set to depart after Sept. 17 annual meeting; CDO Matthew Davidson slated to succeed
Reuters2026/08/13 21:26- Adial Pharmaceuticals flagged a potential leadership reshuffle tied to a shareholder vote at its Sept. 17, 2026 annual meeting.
- CEO Cary Claiborne is expected to be removed promptly following the meeting if the proposals pass.
- Matthew Davidson, chief development officer and a board member, is slated to become president and CEO if the vote clears.
- CFO Vinay Shah is also expected to be removed promptly following the meeting if the proposals pass.
- Board turnover is anticipated, including resignations of legacy directors, though no final decisions have been made.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Why hasn’t the rise in US Treasury yields boosted the US dollar exchange rate?
Gurman predicts iPhone Duo: The first foldable may set industry standards, Apple (AAPL.US) foldable could trigger a decade-long upgrade cycle
Renowned financial journalist Mark Gurman stated that Apple’s first foldable iPhone has the potential to elevate the still-experimental foldable phone category to an industry standard. He noted that this device, called the iPhone Duo, is one of Apple’s most influential products, ranking just behind the iMac, iPod, iPad, and Apple Watch.
Element Fleet drops bid for FleetPartners, exits sale process
Anchoring to Nasdaq! Anthropic races toward a record-breaking IPO with fundraising scale targeting SpaceX
Sources indicate that Anthropic PBC has chosen Nasdaq as its listing venue, and the potential IPO is expected to set a historic record.
Crypto prices
More
